Halozyme Therapeutics (HALO) EBIAT (2016 - 2025)
Historic EBIAT for Halozyme Therapeutics (HALO) over the last 17 years, with Q4 2025 value amounting to -$141.6 million.
- Halozyme Therapeutics' EBIAT fell 20334.2% to -$141.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $316.9 million, marking a year-over-year decrease of 2864.32%. This contributed to the annual value of $316.9 million for FY2025, which is 2864.32% down from last year.
- As of Q4 2025, Halozyme Therapeutics' EBIAT stood at -$141.6 million, which was down 20334.2% from $175.2 million recorded in Q3 2025.
- Halozyme Therapeutics' EBIAT's 5-year high stood at $216.6 million during Q3 2021, with a 5-year trough of -$141.6 million in Q4 2025.
- Over the past 5 years, Halozyme Therapeutics' median EBIAT value was $79.3 million (recorded in 2023), while the average stood at $82.4 million.
- As far as peak fluctuations go, Halozyme Therapeutics' EBIAT skyrocketed by 55707.03% in 2021, and later tumbled by 20334.2% in 2025.
- Over the past 5 years, Halozyme Therapeutics' EBIAT (Quarter) stood at $66.8 million in 2021, then decreased by 13.58% to $57.7 million in 2022, then soared by 47.98% to $85.4 million in 2023, then soared by 60.46% to $137.0 million in 2024, then tumbled by 203.34% to -$141.6 million in 2025.
- Its EBIAT was -$141.6 million in Q4 2025, compared to $175.2 million in Q3 2025 and $165.2 million in Q2 2025.